Gsk's older adult rsv vaccine candidate, containing agenus' qs-21 stimulon™, shows 94.1% reduction in severe rsv disease and overall vaccine efficacy of 82.6% in pivotal trial

Lexington, mass., oct. 13, 2022 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapies and adjuvants designed to activate the immune response to cancer and infections, today shared that gsk has disclosed positive pivotal phase iii trial results for its respiratory syncytial virus (rsv) vaccine candidate for adults aged 60 years and above and plans to present full data at id week on october 20th. the vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% ci, 57.9–94.1) against rsv lower respiratory tract disease (rsv-lrtd), meeting the trial's primary endpoint.
AGEN Ratings Summary
AGEN Quant Ranking